Biosimilars Market Set for Biggest Year Yet in 2023
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. The increase, from ASP plus 6% to ASP plus 8%, will last for five years, and may help increase access to and utilization of biosimilars and promote competition in the marketplace.
Let's personalize your content